Cellusion
cellusion.jp
Actively hiring
Health Care
Cell & Gene Therapy
Regenerative Medicine
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Financials
Overview
Cellusion develops regenerative medicine therapies using induced pluripotent stem (iPS) cells focused on treating corneal endothelial diseases. The company is developing a proprietary minimally invasive cell therapy composed of corneal endothelial cells derived from iPS cells to reduce reliance on donor corneas and highly skilled surgeons. Its product targets patients with corneal blindness worldwide by enabling broader access to transplantation-like treatment options.